Literature DB >> 10586538

Smooth pursuit and saccadic eye movement performance in a prefrontal leukotomy patient.

D C Gooding1, W G Iacono, D R Hanson.   

Abstract

The authors wished to examine the role of the prefrontal cortex in oculomotor performance. They assessed smooth pursuit and saccadic performance in a patient with schizophrenia who had undergone a bilateral prefrontal leukotomy. Her performance on neuropsychological test measures sensitive to frontal lobe functioning were also examined. Against a background of intact intellectual and neurological functioning, the patient displayed a dissociation in premotor and prefrontal functioning. Smooth pursuit performance was within normal limits, as were the patient's finger tapping scores. In contrast, the patient performed poorly on the Wisconsin Card Sorting Test, and verbal and design fluency tasks. Similarly, her performance on the antisaccade task was markedly deviant. Despite advanced age and a frontal leukotomy, this patient with schizophrenia displayed intact smooth pursuit, indicating that the frontal cortex is not necessary for normal smooth pursuit performance.

Entities:  

Mesh:

Year:  1999        PMID: 10586538      PMCID: PMC1189061     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  36 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  The effect of fixation condition manipulations on antisaccade performance in schizophrenia: studies of diagnostic specificity.

Authors:  J E McDowell; B A Clementz
Journal:  Exp Brain Res       Date:  1997-06       Impact factor: 1.972

3.  Relationships between neuropsychological and oculomotor measures in schizophrenia patients and normal controls.

Authors:  A D Radant; K Claypoole; D K Wingerson; D S Cowley; P P Roy-Byrne
Journal:  Biol Psychiatry       Date:  1997-11-01       Impact factor: 13.382

4.  Cortical potentials with antisaccades.

Authors:  I Evdokimidis; D Liakopoulos; T S Constantinidis; C Papageorgiou
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1996-05

5.  Age diminishes performance on an antisaccade eye movement task.

Authors:  A Olincy; R G Ross; D A Youngd; R Freedman
Journal:  Neurobiol Aging       Date:  1997 Sep-Oct       Impact factor: 4.673

6.  Design fluency: the invention of nonsense drawings after focal cortical lesions.

Authors:  M Jones-Gotman; B Milner
Journal:  Neuropsychologia       Date:  1977       Impact factor: 3.139

7.  Abnormal smooth pursuit eye movements in schizophrenic patients are associated with cerebral glucose metabolism in oculomotor regions.

Authors:  D E Ross; G K Thaker; H H Holcomb; N G Cascella; D R Medoff; C A Tamminga
Journal:  Psychiatry Res       Date:  1995-09-08       Impact factor: 3.222

8.  Antisaccade performance in patients with schizophrenia and affective disorder.

Authors:  J Katsanis; S Kortenkamp; W G Iacono; W M Grove
Journal:  J Abnorm Psychol       Date:  1997-08

9.  Smooth pursuit and saccadic abnormalities in first-episode schizophrenia.

Authors:  S B Hutton; T J Crawford; B K Puri; L J Duncan; M Chapman; C Kennard; T R Barnes; E M Joyce
Journal:  Psychol Med       Date:  1998-05       Impact factor: 7.723

10.  Eye movements in schizophrenia.

Authors:  R D Yee; R W Baloh; S R Marder; D L Levy; S M Sakala; V Honrubia
Journal:  Invest Ophthalmol Vis Sci       Date:  1987-02       Impact factor: 4.799

View more
  2 in total

Review 1.  Atypical scanpaths in schizophrenia: evidence of a trait- or state-dependent phenomenon?

Authors:  Sara A Beedie; Philip J Benson; David M St Clair
Journal:  J Psychiatry Neurosci       Date:  2011-05       Impact factor: 6.186

Review 2.  The tell-tale tasks: a review of saccadic research in psychiatric patient populations.

Authors:  Diane C Gooding; Michele A Basso
Journal:  Brain Cogn       Date:  2008-10-23       Impact factor: 2.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.